Free Submission Public Relations &
Deutsch English

Dyax Corp.: Pharmaceuticals and Healthcare Company Profile, SWOT and Financial Report

Dyax Corp.: Pharmaceuticals and Healthcare Company Profile, SWOT and Financial Report - new company profile report published

Print article Print article
2012-12-05 03:12:56 - Dyax Corp.: Pharmaceuticals and Healthcare Company Profile, SWOT and Financial Report - a new company profile report on

Dyax Corp.: Pharmaceuticals and Healthcare - Company Profile and SWOT Report contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, swot analysis, business description, and company history.


This report is a crucial resource for industry executives and anyone looking to access key information about Dyax Corp.

The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.


- Examines and identifies key information and issues about Dyax Corp. for business intelligence requirements.
- Studies



and presents the company´s strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
- Provides data on company financial performance.
- The profile also contains information on business operations, company history, major products and services, key employees, locations and subsidiaries.

Reasons To Buy

- Quickly enhance your understanding of Dyax Corp.
- Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry.
- Increase business/sales activities by understanding your competitors´ businesses better.
- Recognize potential partnerships and suppliers.

Key Highlights

Dyax Corp. (Dyax) is a biopharmaceutical company that specializes in the discovery, development, and commercialization of novel biotherapeutics for inflammatory, oncology and other indications. The company´s lead product candidate, DX-88 received approval from the US FDA (United States Food and Drug Administration) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. It markets its DX-88 under the brand name, KALBITOR (ecallantide) in the US. In addition, the company develops DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals (Cubist), and for the treatment of retinal diseases in collaboration with Fovea Pharmaceuticals (Fovea), a part of sanofi-aventis. Furthermore, Dyax identifies new drug candidates using phage display technology. Its other drug candidates include DX-2240 and DX-2400. Dyax is headquartered in Cambridge, Massachusetts, the US.

Click for report details: ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Company Profile Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Mike King
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact